Literature DB >> 9734634

Planned progressive antimicrobial therapy in neutropenic patients.

C Viscoli1, E Castagnola.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9734634     DOI： 10.1046/j.1365-2141.1998.00848.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  5 in total

Review 1.  Pharmacoeconomic considerations in treating patients with acute leukaemia.

Authors:  V Jønsson; M M Hansen; P Ljungman; S Kaasa
Journal:  Pharmacoeconomics       Date:  1999-02       Impact factor: 4.981

2.  Mortality in a heterogeneous population of low-risk febrile neutropenic patients treated initially with cefazolin and tobramycin.

Authors:  Francesca Le Piane; Sandra An Walker; Scott E Walker; Nina Lathia; Carlo De Angelis; Andrew Simor
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

Review 3.  Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy.

Authors:  Anat Gafter-Gvili; Abigail Fraser; Mical Paul; Liat Vidal; Theresa A Lawrie; Marianne D van de Wetering; Leontien C M Kremer; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2012-01-18

4.  Bacterial Spectrum, Isolation Sites and Susceptibility Patterns of Pathogens in Adult Febrile Neutropenic Cancer Patients at a Specialist Hospital in Saudi Arabia.

Authors:  Mansoor Sirkhazi; Azmi Sarriff; Noorizan Abd Aziz; Fatma Almana; Osama Arafat; Mahmoud Shorman
Journal:  World J Oncol       Date:  2014-12-03

5.  Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen.

Authors:  Alaa M Ali; Daniel Weisel; Feng Gao; Geoffrey L Uy; Amanda F Cashen; Meagan A Jacoby; Lukas D Wartman; Armin Ghobadi; Iskra Pusic; Rizwan Romee; Todd A Fehniger; Keith E Stockerl-Goldstein; Ravi Vij; Stephen T Oh; Camille N Abboud; Mark A Schroeder; Peter Westervelt; John F DiPersio; John S Welch
Journal:  Cancer Med       Date:  2017-10-23       Impact factor: 4.452
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.